BT-003-GMP,
BT-003-AFL, 203-IL; 50 ng/mL), SCF (Catalog #s
BT-SCF-GMP,
BT-SCF-AFL,
BT-SCF; 100 ng/mL), TPO (Catalog #s
BT-TPO-GMP,
BT-TPO-AFL,
BT-TPO; 100 ng/mL), FLT-3L (Catalog #
BT-FT3L-GMP,
BT-FT3L-AFL,
BT-FT3L; 100 ng/mL), and SR1 (Catalog # 7086, 1 µM). After 7 days, frequency (%) of CD34+ cells was analyzed by flow cytometry with an anti-human CD34 monoclonal antibody (Catalog #
MAB7227). CD34+ Cell Expansion is calculated by multiplying Total Nucleated Cell (TNC) fold expansion by the percent CD34+ cells. Cell viability on Day 7 was greater than 90% for all conditions." class="big_lightbox">
BT-003-GMP,
BT-003-AFL, 203-IL; 50 ng/mL), SCF (Catalog #s
BT-SCF-GMP,
BT-SCF-AFL,
BT-SCF; 100 ng/mL), TPO (Catalog #s
BT-TPO-GMP,
BT-TPO-AFL,
BT-TPO; 100 ng/mL), FLT-3L (Catalog #
BT-FT3L-GMP,
BT-FT3L-AFL,
BT-FT3L; 100 ng/mL), and SR1 (Catalog # 7086, 1 µM). After 7 days, frequency (%) of CD34+ cells was analyzed by flow cytometry with an anti-human CD34 monoclonal antibody (Catalog #
MAB7227). CD34+ Cell Expansion is calculated by multiplying Total Nucleated Cell (TNC) fold expansion by the percent CD34+ cells. Cell viability on Day 7 was greater than 90% for all conditions." class="big_thumb" />
714-GR). The activity is approximately 9-fold greater than the top competitor's GDNF." class="big_thumb" />
314-BP). The dark blue line on the graph is showing the ability of Recombinant Human BMP-4 (ng/mL) to induce alkaline phosphatase production in the ATDC5 mouse chondrogenic cell line." class="big_thumb" />
3718-FB) and Recombinant Human Noggin (Catalog # 6057-NG), along with the other reagents listed in the 
brain organoid culture recipe. (A) Representative brightfield image of day 30 iPSC-derived cerebral organoids. (B) Cerebral organoids stained for beta III-tubulin (green) and Prox1 (red), and counterstained with DAPI (blue)." class="big_thumb" />
BT-003-GMP, 
